###begin article-title 0
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression
###end article-title 0
###begin p 1
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 707 711 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 938 942 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 970 977 970 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1077 1080 1077 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc</italic>
###xml 1164 1168 1164 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1266 1270 1266 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 330 335 <span type="species:ncbi:9606">human</span>
The androgen receptor (AR) plays a pivotal role in the onset and progression of prostate cancer by promoting cellular proliferation. Recent studies suggest AR is a master regulator of G1-S progression and possibly a licensing factor for DNA replication yet the mechanisms remain poorly defined. Here we report that AR targets the human Cdc6 gene for transcriptional regulation. Cdc6 is an essential regulator of DNA replication in eukaryotic cells and its mRNA expression is inversely modulated by androgen or antiandrogen treatment in androgen-sensitive prostate cancer cells. AR binds at a distinct androgen-response element (ARE) in the Cdc6 promoter that is functionally required for androgen-dependent Cdc6 transcription. We found that peak AR occupancy at the novel ARE occurs during the G1/S phase concomitant with peak Cdc6 mRNA expression. We also identified several of the coactivators and corepressors involved in AR-dependent Cdc6 transcriptional regulation in vivo and further characterized ligand-induced alterations in histone acetylation and methylation at the Cdc6 promoter. Significantly, AR silencing in prostate cancer cells markedly decreases Cdc6 expression and androgen-dependent cellular proliferation. Collectively, our results suggest that Cdc6 is a key regulatory target for AR and provide new insights into the mechanisms of prostate cancer cell proliferation.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 479 482 479 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2 B3 B4 B5">2&#8211;5</xref>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 790 791 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 944 945 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 946 947 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1092 1099 1092 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Androgens are steroid hormones responsible for the development and functional maintenance of male reproductive and accessory sex tissues. They exert their physiologic actions by binding to the androgen receptor (AR), a 110-kDa member of the nuclear receptor family of ligand-activated transcription factors (1). AR mediates androgen action by binding to specific DNA sequences termed androgen response elements (ARE) found within promoter or enhancer regions of AR-target genes (2-5). When bound with androgen, AR can activate target gene transcription by recruiting distinct coregulatory factors including enzymes that covalently modify histones and remodel chromatin (6,7), as well as the Mediator complex that directly interfaces with the RNA polymerase II (RNA pol II) basal machinery (8,9). When bound with antiandrogenic compounds, AR can repress target gene transcription by recruiting negative coregulatory factors termed corepressors (6,7). Although numerous AR coactivators and corepressors have been reported and characterized, many of the genes directly bound and regulated by AR in vivo remain poorly defined.
###end p 3
###begin p 4
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 760 765 760 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14 B15 B16">14&#8211;16</xref>
###xml 998 999 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
Significantly, AR plays a pivotal role in the onset and progression of prostate cancer by promoting the growth and proliferation of prostate cancer cells (1,10,11). Mechanistic investigations have revealed that AR acts as a master regulator of G1-S phase progression in androgen-dependent prostate cancer cells (12) and that AR protein is degraded at mitosis during each cell cycle (13). These findings suggest that AR may be acting as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells, and that mitotic AR degradation is required to license a new round of DNA replication. Treatment options for prostate cancer include androgen-ablation therapy that initially triggers apoptosis or cell-cycle arrest of prostate cancer cells (14-16). Paradoxically, nearly all invasive or metastatic prostate cancers eventually progress into a fatal androgen-independent disease, yet most of these cancers continue to express AR and remain dependent on AR for growth and survival (1,10,11). Therefore, identifying the specific genes regulated by AR will be critical for understanding the mechanisms of androgen-dependent and -independent prostate cancer cell growth and proliferation.
###end p 4
###begin p 5
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 525 529 525 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 815 820 815 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20 B21 B22">20&#8211;22</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1239 1241 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1279 1283 1279 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1293 1300 1293 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1338 1342 1338 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1412 1414 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1273 1278 <span type="species:ncbi:9606">human</span>
Cdc6 is an essential regulator of DNA replication in eukaryotic cells (17). Along with a subset of other key replication factors, Cdc6 helps form a pre-replication complex at the origins of DNA replication early in G1 phase thereby 'licensing' these sites to bind DNA polymerase and initiate DNA replication during S phase (18,19). The expression and functional activity of Cdc6 is tightly regulated in a cell-cycle-dependent manner thus ensuring that the entire genome is replicated only once in each cell division. Indeed, Cdc6 is considered an oncogene and its deregulated expression can lead to under- or over-replication, DNA damage and genetic instability (18). In mammalian cells, Cdc6 expression peaks during the G1/S transition and is transcriptionally regulated in a cell-cycle- and E2F-dependent manner (20-22). Given AR's presumptive role as a licensing factor for DNA replication, it has been proposed that Cdc6 and possibly other replication factors might be regulatory targets for AR-signaling pathways (13). Interestingly, when synchronized prostate cancer LNCaP cells are treated with the antiandrogenic compound bicalutamide (Casodex), the cells fail to enter S phase and concomitantly downregulate Cdc6 mRNA expression (23). Furthermore, AR binds at the human Cdc6 promoter in vivo and androgens were found to regulate Cdc6 gene expression in AR-positive prostate cancer cells and xenografts (24,25).
###end p 5
###begin p 6
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 476 484 476 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 489 496 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 727 731 727 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1050 1054 1050 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1213 1217 1213 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1267 1271 1267 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 54 59 <span type="species:ncbi:9606">human</span>
In this study, we investigated whether AR targets the human Cdc6 gene for transcriptional regulation in prostate cancer cells in a cell-cycle-dependent manner. Using androgen-sensitive LNCaP cells, we found that Cdc6 mRNA and protein expression is activated or repressed in the presence of androgen or antiandrogen, respectively. We identified a 15 bp palindromic ARE in the Cdc6 promoter (-734 bp upstream of the transcription start site) and show that AR occupies this site in vitro and in vivo. Mutagenesis of the ARE abolishes AR binding as well as androgen-dependent Cdc6 transcription. Intriguingly, and consistent with its presumptive role as a DNA replication licensing factor, we show that peak occupancy of AR at the Cdc6 promoter occurs during the G1/S phase of the cell cycle, concomitant with peak Cdc6 mRNA expression. Silencing AR expression markedly decreases both Cdc6 expression and androgen-dependent cellular proliferation. Significantly, we also identified several specific coactivators and corepressors involved in AR-dependent Cdc6 transcriptional regulation and further characterized androgen- and antiandrogen-induced alterations in histone H3 acetylation and methylation patterns at the Cdc6 promoter. Collectively, our results suggest that Cdc6 is a key regulatory target gene in androgen-responsive prostate cells and may have important implications for prostate cancer cell growth and proliferation.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Cell culture
###end title 8
###begin p 9
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 670 671 664 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 267 273 <span type="species:ncbi:9913">bovine</span>
LNCaP, DU145 and PC3 cells were obtained from the American Type Culture Collection (Manassas, VA). 1532T-f:AR cells were generated and cultured as described previously (26). LNCaP cells were routinely maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS; Gemini Bioproducts) along with penicillin and streptomycin (Invitrogen). DU145 and PC3 cells were grown in DMEM with 10% FBS and penicillin/streptomycin. In the androgen starvation experiments, cells were grown in phenol red-free medium containing charcoal/dextran-stripped FBS (CDS-FBS, Gemini Bioproducts). All cells were maintained in a humidified incubator at 37degreesC and 5% CO2.
###end p 9
###begin title 10
Antibodies and reagents
###end title 10
###begin p 11
###xml 382 393 <span type="species:ncbi:3704">Horseradish</span>
###xml 421 427 <span type="species:ncbi:9986">rabbit</span>
###xml 441 446 <span type="species:ncbi:10090">mouse</span>
Specific antibodies against Cdc6, AR, MED1, MED6, MED14, MED17, SRC1, SRC3, NCoR, SMRT, HDAC1, HDAC2, HDAC3 and alpha-tubulin were all from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against H3R17-2me, H3K4-2me and unmodified Histone 3 were from Abcam (Cambridge, MA) and antibodies against acetylated-H3 and H3K9-3me were from Millipore/Upstate Biotech (Billerica, MA). Horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG were from Cell Signaling (Beverly, MA). Enhanced Chemiluminescence (ECL) reagents were from Amersham Pharmacia/GE Healthcare (Piscataway, NJ). The Luciferase Assay kit was from Promega (Madison, WI) and the dihydrotestosterone (DHT), nocodazole and R1881 were all from Sigma (St Louis, MO). Casodex (Bicalutamide) was generously provided by AstraZeneca (United Kingdom).
###end p 11
###begin title 12
RT-PCR analysis
###end title 12
###begin p 13
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 363 367 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 368 373 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">actin</italic>
###xml 375 377 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
Total RNA was extracted from prostate cancer cell lines using TRIzol reagent (Invitrogen). One microgram of total RNA was incubated with reverse transcriptase (Invitrogen) and 200 mM deoxynucleoside triphosphates (dNTPs) to generate first-strand cDNA and then amplified by PCR using Fast Start Taq polymerase (Roche) with primers specific for either Cdc6 (24) or beta-actin (27) for 25 cycles. The PCR products were then analyzed on 1.5% agarose gel stained with ethidium bromide.
###end p 13
###begin title 14
Real-time PCR
###end title 14
###begin p 15
###xml 135 140 <span type="species:ncbi:9606">Human</span>
###xml 228 234 <span type="species:ncbi:9986">rabbit</span>
PCR was performed using the Opticon Continuous Fluorescence Detection System (MJ Research) using a SYBR(R) Green PCR kit (Invitrogen). Human beta-actin was used as an internal control for real time RT-PCR analyses. Non-specific rabbit IgG was used as an internal control for real time ChIP.
###end p 15
###begin title 16
ChIP analyses
###end title 16
###begin p 17
###xml 432 434 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 435 437 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 624 627 <span type="species:ncbi:9685">cat</span>
###xml 693 696 <span type="species:ncbi:301693">ata</span>
###xml 1007 1010 <span type="species:ncbi:301693">ata</span>
LNCaP cells were cultured in CDS-FBS containing media for 3 days and then treated with DHT (10 nM) for 4 h. For the Casodex treatment, LNCaP cells were cultured in 10% FBS RPMI media and then treated with Casodex (30 muM) for 2 h. Antibodies specific for AR, coactivators, corepressors and covalently modified histones were then used to immunoprecipitate formaldehyde cross-linked chromatin-protein complexes as outlined in detail (28,29). The immunoprecipitated DNA was then analyzed via semi-quantitative and real time PCR using primers spanning the Cdc6 promoter region: Primer set A: forward, 5'-gaa acc cta gtg ttt cgc cat aaa ag-3' (-825 bp), and reverse, 5'-ggt aaa gtt cta cac acc tat ata aag-3'(-604 bp); Primer set B: forward, 5'-gcc ttc acg aaa tgt act cca c-3' (-1394 bp), and reverse, 5'-caa cta gta agt gga aga gct ag-3' (-1254 bp); Primer set C: forward, 5'-gct ctc tca ttg gct gta act c-3' (-149 bp), and reverse, 5'-cgc tcg cgc caa atc cga atg-3' (+5 bp); Primer set D: forward, 5'-gag act ata act cta cag att g-3' (+14976 bp), and reverse, 5'-ctt gaa aca agt ggc ttc atc-3' (+15152 bp). All ChIP experiments were carried out at least three times. Image processing and quantitation of the semi-quantitative PCR data was performed using the Quantity One software (Bio-Rad) ().
###end p 17
###begin title 18
Plasmids
###end title 18
###begin p 19
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 398 402 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 829 831 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 520 523 <span type="species:ncbi:301693">ata</span>
###xml 880 883 <span type="species:ncbi:301693">ata</span>
###xml 884 887 <span type="species:ncbi:301693">ata</span>
The pGL3-Cdc6-1.7-kb promoter-Luc plasmid was provided by Dr Joseph Nevins (Duke) and has been described previously (20). The pSG5-AR construct was provided by Dr Frank Claessens (Katholieke Universiteit Leuven), the pRSV-TRbeta vector was from Dr Herb Samuels (NYU) and the pCMV-GR construct was from Dr Michael Garabedian (NYU). The pGL2-Cdc6-ARE construct was generated by PCR by amplifying the Cdc6 promoter region containing the putative ARE and GATA sites (bps -781 to -575) using primers (forward) 5'-ggg gta ccc ata att ccc tcc cca tga tgt gtg g-3' and (reverse) 5'-gaa gat ctc tcc tga tgg ctg aac tag tga ttt tta tgg-3' and then subcloning the amplified fragment into pGL2-Basic (Promega, Madison, WI). The pGL2-Cdc6-AREmt construct was created via PCR-generated mutagenesis of the pGL2-Cdc6-ARE construct as described (30) using primers (forward) 5'-gaa gat gca caA GGc ata ata ttc tta ggt tg-3' and (reverse) 5'-cct aag aat att atg CCT tgt gca tct tc-3'. The pGL2-Cdc6-GATA-mt.1 and pGL2-Cdc6-GATA-mt.2 constructs were generated via PCR-generated mutagenesis using primers (forward) 5'-gca caa atc aag act tac tat gat gaa gc-3 and (reverse) 5'-gct tca tca tag taa gtc ttg att tgt gc-3' for mutant 1 and primers (forward) 5'-gca caa atc aag aac cac tat gat gaa gc-3' and (reverse) 5'-gct tca tca tag tgg ttc ttg att tgt gc-3' for mutant 2.
###end p 19
###begin title 20
Luciferase reporter gene assays
###end title 20
###begin p 21
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 724 725 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
LNCaP cells were cultured in CDS-FBS containing media for 3 days and then seeded (1 x 105 cells) in 12-well plates and transfected with 100 ng pGL3-Cdc6-1.7 kb or empty pGL3 control using Lipofectamine PLUS reagent (Invitrogen, Carlsbad, CA). In separate experiments, 500 ng of either pGL2-Cdc6-ARE, pGL2-Cdc6-AREmt, pGL2-Cdc6-GATA-mt.1, pGL2-Cdc6-GATA-mt.2, or empty pGL2 control were transfected via Lipofectamine PLUS reagent. Three hours post-transfection, the medium was replaced with fresh media containing or lacking R1881 (10 nM final) for an additional 24 h. For experiments involving addition of Casodex, cells were grown in normal FBS prior to transfection. DU145 cells grown in normal 10% FBS were seeded (1 x 105 cells) in 12-well plates and cotransfected with 500 ng of pGL2-Cdc6-ARE and 500 ng of either pSG5-AR, pCMV-GR, pRSV-TRbeta, or their corresponding empty vectors via Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Three hours post-transfection, the medium was replaced with fresh media containing or lacking R1881 (10 nM), Dexamethasone (10 nM final), or T3 (100 nM) for an additional 24 h. Cells were harvested and equivalent amounts of protein were assayed for luciferase activity using an assay kit (Promega) and a luminometer. Luciferase values were normalized by using a beta-galactosidase (pSV-ssgal) (Promega) expression vector as internal control.
###end p 21
###begin title 22
Electromobility shift assay
###end title 22
###begin p 23
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 566 568 562 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 851 853 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1136 1138 1116 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 410 414 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 693 698 <span type="species:ncbi:9606">human</span>
###xml 1038 1044 <span type="species:ncbi:9913">bovine</span>
The wild-type Cdc6 promoter ARE oligo 5'GAA GAT GCA CAG AAC ATA ATA TTC TTA GGT TG3' and its complementary strand were annealed generating a double-stranded template with protruding BglII ends. Similarly, the mutant ARE oligo 5'GGT AAG AAG ATG CAC AAT ATT CTT AGG TTG3' and its complement were annealed generating a double-stranded template with protruding BglII ends. As a positive control, a double-stranded MMTV long terminal repeat promoter ARE template was generated as described previously (26). The double-stranded AREs were labeled by filling in with [alpha-32P]dATP (50 microCi; Amersham Biosciences) and Klenow enzyme. To purify the full-length AR protein used for EMSA, FLAG-tagged human AR (f:AR) was immunopurified from a stable 1532T-f:AR cell line using anti-FLAG M2 antibodies coupled to agarose beads (Sigma) as described previously (26). Purified f:AR protein was incubated for 15 min at room temperature in binding buffer containing 10 mM Tris-Cl (pH 7.9), 50 mM KCl, 1 mM dithiothreitol, 10% glycerol, 1 microg/microl bovine serum albumin, 0.5 microg of poly (dI-dC), 1 mM EDTA, 0.1% Nonidet P-40 along with 2 ng of 32P-labeled double-stranded ARE probe. The reactions were electrophoresed in a prerun 5% polyacrylamide gel, 0.5x Tris borate-EDTA at 100 V for 3-4 h. The gel was then dried and autoradiographed.
###end p 23
###begin title 24
RNA interference
###end title 24
###begin p 25
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
AR siRNA was generated using the Silencer siRNA Construction Kit (Ambion) using the specific target sequence 5'-GAC CTA CCG AGG AGC TTT C-3' as previously outlined (31). A scrambled non-specific siRNA smart pool was from Dharmacon Research, Inc., as previously described (27). The AR siRNA (200 nM final) was transfected into LNCaP cells using Lipofectamine with Plus reagent.
###end p 25
###begin title 26
Cell proliferation assay
###end title 26
###begin p 27
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
LNCaP cells were androgen-starved in RPMI media containing 10% CDS-FBS for 48 h and then seeded (1 x 105 cells) in 12-well plates and transfected with AR siRNA or a non-specific control siRNA (200 nM final). Forty-eight hours post-transfection, the cells were trypsinized and seeded (5 x 104) in 12-well plates and allowed to proliferate for an additional 48 h in CDS-FBS with or without 10 nM DHT or 30 microM Casodex. Cell proliferation was measured by manually counting cell numbers. Experiments were performed in quadruplicate.
###end p 27
###begin title 28
LNCaP cell synchronization
###end title 28
###begin p 29
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
LNCaP cells cultured in normal serum were seeded 5 x 105 cells per 6-well plate and then transfected with AR siRNA or a non-specific control siRNA (200 nM final). The cells were either arrested at the border of G1/S using the double-thymidine-block methodology as described previously (32) or arrested in G2/M by treating the cells with 100 ng/ml nocodazole for 18 h. Then cells were then harvested for RT-PCR, immunoblot or ChIP analyses as described above. Synchronization was verified by fixing and staining the cells with propidium iodide (20 microg/ml) and then analyzing them using a Cytomics FC500 flow cytometer (Beckman Coulter Inc.).
###end p 29
###begin title 30
RESULTS
###end title 30
###begin title 31
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Cdc6 expression in LNCaP cells is modulated in an androgen- and antiandrogen-dependent fashion
###end title 31
###begin p 32
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 461 465 461 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 891 895 891 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 455 460 <span type="species:ncbi:9606">human</span>
###xml 804 809 <span type="species:ncbi:9606">human</span>
Several previous studies indirectly link AR-signaling pathways with Cdc6 expression in androgen-sensitive prostate cancer cells. For example, when AR-expressing prostate cancer LNCaP cells are synchronized in the G0/G1 phase of the cell cycle and then treated with the antiandrogenic compound Casodex, the cells fail to enter S phase and concomitantly downregulate Cdc6 mRNA expression (23). Similarly, a significant loss of transcription efficiency of a human Cdc6 promoter-reporter gene was noted in AR-negative prostate cancer cells as compared with that observed in AR-positive prostate cells (24). Moreover, previous LNCaP gene array studies have shown that Cdc6 mRNA expression increases in the presence of androgen (33) and decreases in the presence of the antiandrogen (23). Indeed, we performed human gene microarray analyses with androgen-sensitive LNCaP cells and also identified Cdc6 as an androgen-responsive gene (data not shown).
###end p 32
###begin p 33
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 297 305 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 714 722 714 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 901 909 901 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1129 1138 1129 1138 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1263 1264 1263 1264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1269 1270 1269 1270 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1375 1376 1375 1376 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1381 1382 1381 1382 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1642 1646 1642 1646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1651 1661 1651 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
###xml 1873 1874 1868 1869 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1879 1880 1874 1875 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 2062 2066 2057 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 2071 2081 2066 2073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
###xml 1138 2100 1138 2092 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="34">Cdc6 expression in androgen-sensitive prostate cancer cells is modulated in an androgen- and antiandrogen-dependent manner. (<bold>A</bold> and <bold>C</bold>) LNCaP cells were androgen-starved for 72 h and then treated with different concentrations of DHT 8 h. (<bold>B</bold> and <bold>D</bold>) Androgen-starved LNCaP cells were first cultured in CDS&#8211;FBS media with 10 nM R1881 for 24 h to elevate basal Cdc6 expression, and then were treated with different concentrations of Casodex for 8 h. Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;-actin</italic> (A and B). Bar graph represents results as the mean &#177; S.E. of triplicate reactions. Twenty-five micrograms of whole cell extract was probed by immunoblot with anti-Cdc6 and anti-tubulin antibodies (C and D). (<bold>E</bold> and <bold>F</bold>) DU145 cells were androgen-starved for 3 days and then treated with different concentrations of DHT and Casodex for 8 h. Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;-actin</italic> as outlined above.</p>
###xml 1138 2100 1138 2092 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="34">Cdc6 expression in androgen-sensitive prostate cancer cells is modulated in an androgen- and antiandrogen-dependent manner. (<bold>A</bold> and <bold>C</bold>) LNCaP cells were androgen-starved for 72 h and then treated with different concentrations of DHT 8 h. (<bold>B</bold> and <bold>D</bold>) Androgen-starved LNCaP cells were first cultured in CDS&#8211;FBS media with 10 nM R1881 for 24 h to elevate basal Cdc6 expression, and then were treated with different concentrations of Casodex for 8 h. Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;-actin</italic> (A and B). Bar graph represents results as the mean &#177; S.E. of triplicate reactions. Twenty-five micrograms of whole cell extract was probed by immunoblot with anti-Cdc6 and anti-tubulin antibodies (C and D). (<bold>E</bold> and <bold>F</bold>) DU145 cells were androgen-starved for 3 days and then treated with different concentrations of DHT and Casodex for 8 h. Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;-actin</italic> as outlined above.</p></caption>
###xml 2100 2100 2092 2092 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f1"/>
###xml 1129 2100 1129 2092 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="34">Cdc6 expression in androgen-sensitive prostate cancer cells is modulated in an androgen- and antiandrogen-dependent manner. (<bold>A</bold> and <bold>C</bold>) LNCaP cells were androgen-starved for 72 h and then treated with different concentrations of DHT 8 h. (<bold>B</bold> and <bold>D</bold>) Androgen-starved LNCaP cells were first cultured in CDS&#8211;FBS media with 10 nM R1881 for 24 h to elevate basal Cdc6 expression, and then were treated with different concentrations of Casodex for 8 h. Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;-actin</italic> (A and B). Bar graph represents results as the mean &#177; S.E. of triplicate reactions. Twenty-five micrograms of whole cell extract was probed by immunoblot with anti-Cdc6 and anti-tubulin antibodies (C and D). (<bold>E</bold> and <bold>F</bold>) DU145 cells were androgen-starved for 3 days and then treated with different concentrations of DHT and Casodex for 8 h. Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;-actin</italic> as outlined above.</p></caption><graphic xlink:href="gkp510f1"/></fig>
In an effort to validate our microarray data linking androgen stimulation with Cdc6 expression, RNA was extracted from LNCaP cells treated with either androgen (dihydrotestosterone or DHT) or antiandrogen (Casodex) and then analyzed by RT-PCR using primers specific for the Cdc6 gene. As shown in Figure 1A and B, and in agreement with the previous microarray studies, Cdc6 mRNA increased in a DHT dose-dependent manner as much as 3-fold, whereas Cdc6 mRNA decreased in the presence of increasing concentrations of Casodex as much as 5-fold. Immunoblot analyses showed that DHT- or Casodex-induced increases or decreases in Cdc6 mRNA were accompanied by a corresponding increase or decrease in protein expression (Figure 1C and D). By contrast, when AR-negative DU145 prostate cancer cells were treated with either DHT or Casodex, no significant increase or decrease in Cdc6 mRNA levels was detected (Figure 1E and F). Taken together, our findings show that androgens and antiandrogens modulate Cdc6 mRNA and protein expression in androgen-sensitive prostate cancer cells, but not in prostate cancer cells lacking AR expression. Figure 1.Cdc6 expression in androgen-sensitive prostate cancer cells is modulated in an androgen- and antiandrogen-dependent manner. (A and C) LNCaP cells were androgen-starved for 72 h and then treated with different concentrations of DHT 8 h. (B and D) Androgen-starved LNCaP cells were first cultured in CDS-FBS media with 10 nM R1881 for 24 h to elevate basal Cdc6 expression, and then were treated with different concentrations of Casodex for 8 h. Total RNA was analyzed by RT-PCR using primers specific for Cdc6 and beta-actin (A and B). Bar graph represents results as the mean +/- S.E. of triplicate reactions. Twenty-five micrograms of whole cell extract was probed by immunoblot with anti-Cdc6 and anti-tubulin antibodies (C and D). (E and F) DU145 cells were androgen-starved for 3 days and then treated with different concentrations of DHT and Casodex for 8 h. Total RNA was analyzed by RT-PCR using primers specific for Cdc6 and beta-actin as outlined above.
###end p 33
###begin p 34
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 131 132 131 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 237 238 237 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 243 244 243 244 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 513 523 513 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
###xml 735 736 730 731 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 741 742 736 737 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 924 928 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 933 943 928 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
Cdc6 expression in androgen-sensitive prostate cancer cells is modulated in an androgen- and antiandrogen-dependent manner. (A and C) LNCaP cells were androgen-starved for 72 h and then treated with different concentrations of DHT 8 h. (B and D) Androgen-starved LNCaP cells were first cultured in CDS-FBS media with 10 nM R1881 for 24 h to elevate basal Cdc6 expression, and then were treated with different concentrations of Casodex for 8 h. Total RNA was analyzed by RT-PCR using primers specific for Cdc6 and beta-actin (A and B). Bar graph represents results as the mean +/- S.E. of triplicate reactions. Twenty-five micrograms of whole cell extract was probed by immunoblot with anti-Cdc6 and anti-tubulin antibodies (C and D). (E and F) DU145 cells were androgen-starved for 3 days and then treated with different concentrations of DHT and Casodex for 8 h. Total RNA was analyzed by RT-PCR using primers specific for Cdc6 and beta-actin as outlined above.
###end p 34
###begin title 35
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Identification of an AR-binding site in the Cdc6 promoter
###end title 35
###begin p 36
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 445 453 445 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 735 739 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 886 894 886 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 989 993 989 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1041 1048 1041 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1195 1199 1195 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1210 1218 1210 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1302 1306 1302 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1461 1469 1461 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1624 1626 1624 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1629 1637 1629 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1641 1650 1641 1650 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1666 1670 1666 1670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1676 1683 1676 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1733 1735 1733 1735 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A</bold>
###xml 1763 1767 1763 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1925 1926 1925 1926 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1966 1970 1966 1970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 2069 2070 2069 2070 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1650 2274 1650 2274 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="37">AR binds at the <italic>Cdc6</italic> gene <italic>in vivo</italic> in a promoter region containing a consensus ARE. <bold>(A</bold>) DNA sequence of the human <italic>Cdc6</italic> promoter region. The ARE is boxed, E2F sites are capitalized and underlined, the GATA site is capitalized and in italics, and the ETS sites are underlined. (<bold>B</bold>) Schematic representation of the human <italic>Cdc6</italic> promoter showing relative location of three PCR primer sets (A, B and C) used for ChIP analyses. (<bold>C</bold>) Chromatin prepared from LNCaP and 1532T-f:AR cells cultured in normal serum was used for ChIP along with anti-AR antibodies. Semi-quantitative PCR was performed using the three primer sets shown in (B).</p>
###xml 1650 2274 1650 2274 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="37">AR binds at the <italic>Cdc6</italic> gene <italic>in vivo</italic> in a promoter region containing a consensus ARE. <bold>(A</bold>) DNA sequence of the human <italic>Cdc6</italic> promoter region. The ARE is boxed, E2F sites are capitalized and underlined, the GATA site is capitalized and in italics, and the ETS sites are underlined. (<bold>B</bold>) Schematic representation of the human <italic>Cdc6</italic> promoter showing relative location of three PCR primer sets (A, B and C) used for ChIP analyses. (<bold>C</bold>) Chromatin prepared from LNCaP and 1532T-f:AR cells cultured in normal serum was used for ChIP along with anti-AR antibodies. Semi-quantitative PCR was performed using the three primer sets shown in (B).</p></caption>
###xml 2274 2274 2274 2274 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f2"/>
###xml 1641 2274 1641 2274 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="37">AR binds at the <italic>Cdc6</italic> gene <italic>in vivo</italic> in a promoter region containing a consensus ARE. <bold>(A</bold>) DNA sequence of the human <italic>Cdc6</italic> promoter region. The ARE is boxed, E2F sites are capitalized and underlined, the GATA site is capitalized and in italics, and the ETS sites are underlined. (<bold>B</bold>) Schematic representation of the human <italic>Cdc6</italic> promoter showing relative location of three PCR primer sets (A, B and C) used for ChIP analyses. (<bold>C</bold>) Chromatin prepared from LNCaP and 1532T-f:AR cells cultured in normal serum was used for ChIP along with anti-AR antibodies. Semi-quantitative PCR was performed using the three primer sets shown in (B).</p></caption><graphic xlink:href="gkp510f2"/></fig>
###xml 1757 1762 <span type="species:ncbi:9606">human</span>
###xml 1960 1965 <span type="species:ncbi:9606">human</span>
In view of the importance of Cdc6 in regulating eukaryotic DNA replication, we were interested in determining whether AR directly targets the Cdc6 gene for transcriptional regulation. Interestingly, a search of the Cdc6 promoter region for potential AR-binding sites revealed the presence of a canonical class I steroid hormone response element (AGAACAnnnTATTCT) (34) spanning positions -734 to -720-bp upstream of the transcription start site (Figure 2A). It has been reported that binding sites for the GATA and ETS families of transcription factors are enriched proximal to cognate AR-binding sites in the genome and may play cooperative roles in mediating an androgen response (3,5,35). Notably, a GATA element was detected in the Cdc6 gene promoter just downstream of the putative ARE at position -656 bp and three ETS-binding sites were found at positions -355, -326 and -211 bp (Figure 2A). To determine whether endogenously expressed AR in LNCaP cells directly associates with the Cdc6 promoter at or near to the putative ARE region in vivo, we performed chromatin-immunoprecipitation (ChIP) assays using an anti-AR antibody and PCR primer sets corresponding to different regions of the Cdc6 promoter (Figure 2B). Utilizing LNCaP cells cultured in normal serum, we detected AR occupancy at the Cdc6 gene-promoter region containing the putative ARE, but not at an upstream-promoter region, nor at a downstream region containing the E2F-binding elements (Figure 2C). Identical results were observed when ChIP was performed using prostate cancer 1532T cells stably transfected with ectopic FLAG-tagged AR (1532T-f:AR) (26) (Figure 2C). Figure 2.AR binds at the Cdc6 gene in vivo in a promoter region containing a consensus ARE. (A) DNA sequence of the human Cdc6 promoter region. The ARE is boxed, E2F sites are capitalized and underlined, the GATA site is capitalized and in italics, and the ETS sites are underlined. (B) Schematic representation of the human Cdc6 promoter showing relative location of three PCR primer sets (A, B and C) used for ChIP analyses. (C) Chromatin prepared from LNCaP and 1532T-f:AR cells cultured in normal serum was used for ChIP along with anti-AR antibodies. Semi-quantitative PCR was performed using the three primer sets shown in (B).
###end p 36
###begin p 37
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 83 85 83 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A</bold>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 275 276 275 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 419 420 419 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 310 315 <span type="species:ncbi:9606">human</span>
AR binds at the Cdc6 gene in vivo in a promoter region containing a consensus ARE. (A) DNA sequence of the human Cdc6 promoter region. The ARE is boxed, E2F sites are capitalized and underlined, the GATA site is capitalized and in italics, and the ETS sites are underlined. (B) Schematic representation of the human Cdc6 promoter showing relative location of three PCR primer sets (A, B and C) used for ChIP analyses. (C) Chromatin prepared from LNCaP and 1532T-f:AR cells cultured in normal serum was used for ChIP along with anti-AR antibodies. Semi-quantitative PCR was performed using the three primer sets shown in (B).
###end p 37
###begin p 38
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 76 84 76 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 306 310 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMTV</italic>
###xml 416 424 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 518 522 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 820 828 820 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 872 876 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1017 1025 1017 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1120 1124 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1129 1137 1129 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1324 1328 1324 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1422 1430 1422 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1498 1502 1498 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1518 1527 1518 1527 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 1552 1556 1552 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1561 1569 1561 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1598 1601 1598 1601 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</bold>
###xml 1723 1725 1723 1725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1748 1750 1748 1750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1765 1769 1765 1769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1832 1836 1832 1836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1847 1851 1847 1851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMTV</italic>
###xml 2261 2262 2261 2262 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2358 2360 2358 2360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 2375 2379 2375 2379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1527 2423 1527 2423 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="39">AR directly binds to the <italic>Cdc6</italic> ARE <italic>in vitro</italic> in the presence of ligand. (<bold>A&#8211;D</bold>) Full-length human FLAG-AR (f:AR) purified from DHT-cultured prostate cancer 1532T cells stably expressing ectopic f:AR (<xref ref-type="bibr" rid="B26">26</xref>) was incubated with a <sup>32</sup>P-radiolabeled <italic>Cdc6</italic> ARE and then assayed by EMSA (see Methods section). A mutated <italic>Cdc6</italic> ARE and a <italic>MMTV</italic> long terminal repeat promoter ARE were used as negative and positive controls, respectively. In (B), equal amounts of f:AR purified from either androgen-starved (&#8722;DHT) or DHT-treated (+DHT) 1532T-f:AR cells was used. In (C), anti-AR antibodies were added to the binding reaction as indicated. In (D), a molar excess of cold unlabeled wild-type ARE or mutated ARE was added to binding reactions as indicated. (<bold>E</bold>) Nuclear extract prepared from DHT-treated LNCaP or PC3 cells was incubated with the wild-type <sup>32</sup>P-radiolabeled <italic>Cdc6</italic> ARE and assayed by EMSA as described above.</p>
###xml 1527 2423 1527 2423 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="39">AR directly binds to the <italic>Cdc6</italic> ARE <italic>in vitro</italic> in the presence of ligand. (<bold>A&#8211;D</bold>) Full-length human FLAG-AR (f:AR) purified from DHT-cultured prostate cancer 1532T cells stably expressing ectopic f:AR (<xref ref-type="bibr" rid="B26">26</xref>) was incubated with a <sup>32</sup>P-radiolabeled <italic>Cdc6</italic> ARE and then assayed by EMSA (see Methods section). A mutated <italic>Cdc6</italic> ARE and a <italic>MMTV</italic> long terminal repeat promoter ARE were used as negative and positive controls, respectively. In (B), equal amounts of f:AR purified from either androgen-starved (&#8722;DHT) or DHT-treated (+DHT) 1532T-f:AR cells was used. In (C), anti-AR antibodies were added to the binding reaction as indicated. In (D), a molar excess of cold unlabeled wild-type ARE or mutated ARE was added to binding reactions as indicated. (<bold>E</bold>) Nuclear extract prepared from DHT-treated LNCaP or PC3 cells was incubated with the wild-type <sup>32</sup>P-radiolabeled <italic>Cdc6</italic> ARE and assayed by EMSA as described above.</p></caption>
###xml 2423 2423 2423 2423 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f3"/>
###xml 1518 2423 1518 2423 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="39">AR directly binds to the <italic>Cdc6</italic> ARE <italic>in vitro</italic> in the presence of ligand. (<bold>A&#8211;D</bold>) Full-length human FLAG-AR (f:AR) purified from DHT-cultured prostate cancer 1532T cells stably expressing ectopic f:AR (<xref ref-type="bibr" rid="B26">26</xref>) was incubated with a <sup>32</sup>P-radiolabeled <italic>Cdc6</italic> ARE and then assayed by EMSA (see Methods section). A mutated <italic>Cdc6</italic> ARE and a <italic>MMTV</italic> long terminal repeat promoter ARE were used as negative and positive controls, respectively. In (B), equal amounts of f:AR purified from either androgen-starved (&#8722;DHT) or DHT-treated (+DHT) 1532T-f:AR cells was used. In (C), anti-AR antibodies were added to the binding reaction as indicated. In (D), a molar excess of cold unlabeled wild-type ARE or mutated ARE was added to binding reactions as indicated. (<bold>E</bold>) Nuclear extract prepared from DHT-treated LNCaP or PC3 cells was incubated with the wild-type <sup>32</sup>P-radiolabeled <italic>Cdc6</italic> ARE and assayed by EMSA as described above.</p></caption><graphic xlink:href="gkp510f3"/></fig>
###xml 158 163 <span type="species:ncbi:9606">human</span>
###xml 306 310 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1615 1620 <span type="species:ncbi:9606">human</span>
###xml 1847 1851 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
We next tested whether recombinant AR can specifically bind to the Cdc6 ARE in vitro by performing DNA electromobility shift assays. Accordingly, full-length human FLAG-AR (f:AR) was purified from 1532T-f:AR cells as described (26) and then incubated with a radiolabeled Cdc6 ARE. A mutated Cdc6 ARE and a MMTV long terminal repeat promoter ARE were used as negative and positive controls, respectively. As shown in Figure 3A and B, f:AR purified from DHT-treated 1532T-f:AR cells bound efficiently with the wild-type Cdc6 ARE but not with mutated Cdc6 ARE, whereas f:AR purified from androgen-starved cells bound only weakly to the wild-type Cdc6 ARE. Addition of an anti-AR antibody confirmed the presence of AR in the protein-DNA complex and as previously reported, dramatically enhanced the AR:ARE interaction (36) (Figure 3C). The binding specificity of f:AR for the Cdc6 ARE was confirmed by the ability of a molar excess of unlabeled wild-type ARE to compete for and inhibit binding with the radiolabeled ARE (Figure 3D). To confirm that endogenously expressed AR from prostate cancer cells directly binds to the Cdc6 ARE in vitro, we performed DNA electromobility assays using nuclear extract prepared from either AR-positive LNCaP cells or AR-negative PC3 cells. As expected, LNCaP nuclear extract exhibited strong Cdc6 ARE-binding activity, whereas no binding activity was observed with the PC3 nuclear extract (Figure 3E). In sum, these results show that AR directly binds to ARE in the Cdc6 gene promoter. Figure 3.AR directly binds to the Cdc6 ARE in vitro in the presence of ligand. (A-D) Full-length human FLAG-AR (f:AR) purified from DHT-cultured prostate cancer 1532T cells stably expressing ectopic f:AR (26) was incubated with a 32P-radiolabeled Cdc6 ARE and then assayed by EMSA (see Methods section). A mutated Cdc6 ARE and a MMTV long terminal repeat promoter ARE were used as negative and positive controls, respectively. In (B), equal amounts of f:AR purified from either androgen-starved (-DHT) or DHT-treated (+DHT) 1532T-f:AR cells was used. In (C), anti-AR antibodies were added to the binding reaction as indicated. In (D), a molar excess of cold unlabeled wild-type ARE or mutated ARE was added to binding reactions as indicated. (E) Nuclear extract prepared from DHT-treated LNCaP or PC3 cells was incubated with the wild-type 32P-radiolabeled Cdc6 ARE and assayed by EMSA as described above.
###end p 38
###begin p 39
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 71 74 71 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</bold>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 238 242 238 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMTV</italic>
###xml 734 735 734 735 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 831 833 831 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 848 852 848 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 320 324 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
AR directly binds to the Cdc6 ARE in vitro in the presence of ligand. (A-D) Full-length human FLAG-AR (f:AR) purified from DHT-cultured prostate cancer 1532T cells stably expressing ectopic f:AR (26) was incubated with a 32P-radiolabeled Cdc6 ARE and then assayed by EMSA (see Methods section). A mutated Cdc6 ARE and a MMTV long terminal repeat promoter ARE were used as negative and positive controls, respectively. In (B), equal amounts of f:AR purified from either androgen-starved (-DHT) or DHT-treated (+DHT) 1532T-f:AR cells was used. In (C), anti-AR antibodies were added to the binding reaction as indicated. In (D), a molar excess of cold unlabeled wild-type ARE or mutated ARE was added to binding reactions as indicated. (E) Nuclear extract prepared from DHT-treated LNCaP or PC3 cells was incubated with the wild-type 32P-radiolabeled Cdc6 ARE and assayed by EMSA as described above.
###end p 39
###begin title 40
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
The Cdc6 promoter ARE confers androgen-dependent transcriptional activation
###end title 40
###begin p 41
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 186 194 186 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 563 571 563 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 767 771 767 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 906 910 906 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1012 1020 1012 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1109 1117 1109 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1171 1175 1171 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1324 1332 1324 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1403 1411 1403 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1415 1424 1415 1424 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1435 1439 1435 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1505 1506 1505 1506 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1542 1546 1542 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1580 1581 1580 1581 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1757 1758 1757 1758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1882 1883 1878 1879 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2053 2054 2049 2050 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2055 2056 2051 2052 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1424 2452 1424 2446 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="42">The ARE in <italic>Cdc6</italic> promoter confers androgen-dependent transcriptional activation. (<bold>A</bold>) Schematic representation of human <italic>Cdc6</italic> promoter-luciferase constructs. (<bold>B</bold>) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the pGL3-Cdc6-1.7 kb reporter construct and then treated with or without 10 nM R1881 for 24 h. (<bold>C</bold>) LNCaP cells cultured in 10% FBS were transfected with pGL3-Cdc6-1.7 kb and then treated with 30 &#181;M Casodex for 10 h. (<bold>D</bold>) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the indicated reporter constructs and then treated with or without 10 nM R1881 for 24 h. (<bold>E</bold>&#8211;<bold>G</bold>) DU145 cells cultured in 10% FBS were cotransfected with pGL2-Cdc6-ARE and the indicated nuclear receptor expression constructs and then treated with or without 10 nM R1881 (panel E) 10 nM dexamethasone (panel F) or 100 nM T3 (panel G) for 24 h. Whole cell extract were prepared and assayed for luciferase activity. Luciferase values are presented as the mean &#177; SE of triplicate transfections.</p>
###xml 1424 2452 1424 2446 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="42">The ARE in <italic>Cdc6</italic> promoter confers androgen-dependent transcriptional activation. (<bold>A</bold>) Schematic representation of human <italic>Cdc6</italic> promoter-luciferase constructs. (<bold>B</bold>) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the pGL3-Cdc6-1.7 kb reporter construct and then treated with or without 10 nM R1881 for 24 h. (<bold>C</bold>) LNCaP cells cultured in 10% FBS were transfected with pGL3-Cdc6-1.7 kb and then treated with 30 &#181;M Casodex for 10 h. (<bold>D</bold>) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the indicated reporter constructs and then treated with or without 10 nM R1881 for 24 h. (<bold>E</bold>&#8211;<bold>G</bold>) DU145 cells cultured in 10% FBS were cotransfected with pGL2-Cdc6-ARE and the indicated nuclear receptor expression constructs and then treated with or without 10 nM R1881 (panel E) 10 nM dexamethasone (panel F) or 100 nM T3 (panel G) for 24 h. Whole cell extract were prepared and assayed for luciferase activity. Luciferase values are presented as the mean &#177; SE of triplicate transfections.</p></caption>
###xml 2452 2452 2446 2446 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f4"/>
###xml 1415 2452 1415 2446 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="42">The ARE in <italic>Cdc6</italic> promoter confers androgen-dependent transcriptional activation. (<bold>A</bold>) Schematic representation of human <italic>Cdc6</italic> promoter-luciferase constructs. (<bold>B</bold>) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the pGL3-Cdc6-1.7 kb reporter construct and then treated with or without 10 nM R1881 for 24 h. (<bold>C</bold>) LNCaP cells cultured in 10% FBS were transfected with pGL3-Cdc6-1.7 kb and then treated with 30 &#181;M Casodex for 10 h. (<bold>D</bold>) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the indicated reporter constructs and then treated with or without 10 nM R1881 for 24 h. (<bold>E</bold>&#8211;<bold>G</bold>) DU145 cells cultured in 10% FBS were cotransfected with pGL2-Cdc6-ARE and the indicated nuclear receptor expression constructs and then treated with or without 10 nM R1881 (panel E) 10 nM dexamethasone (panel F) or 100 nM T3 (panel G) for 24 h. Whole cell extract were prepared and assayed for luciferase activity. Luciferase values are presented as the mean &#177; SE of triplicate transfections.</p></caption><graphic xlink:href="gkp510f4"/></fig>
###xml 352 357 <span type="species:ncbi:9606">human</span>
###xml 1536 1541 <span type="species:ncbi:9606">human</span>
We next sought to determine whether the ARE in the Cdc6 gene promoter is responsible for the androgen-induced increase in Cdc6 mRNA observed in androgen-sensitive prostate cancer cells (Figure 1). To address this question, we first measured transcription from a Cdc6 promoter-luciferase reporter gene (pGL3-Cdc6-1.7 kb) containing 1.7 kb of the native human Cdc6 promoter region (-1700 to +7) (20). Androgen-starved LNCaP cells were transfected with either pGL3-Cdc6-1.7 kb or an empty pGL3 control and then cultured with or without the synthetic androgen R1881 (Figure 4B). Basal expression from the pGL3-Cdc6-1.7 kb construct (minus R1881) was considerably higher than that observed with the pGL3 control, presumably due to the presence of Sp1 and E2F sites in the Cdc6 promoter construct near the transcription start site. Consistent with the idea that the ARE region is required for androgen-dependent Cdc6 transcription, addition of R1881 stimulated transcription from pGL3-Cdc6-1.7 kb greater than 2-fold (Figure 4B), whereas addition of the antiandrogen Casodex reduced transcription by nearly 2-fold (Figure 4C). Moreover, androgen-dependent transcription from a Cdc6 promoter reporter construct (pGL2-Cdc6-ARE) containing only the ARE and GATA region (bps -781 to -575) was stimulated nearly 4-fold in LNCaP cells (Figure 4D) and in prostate cancer DU145 cells transiently transfected with AR (Figure 4E). Figure 4.The ARE in Cdc6 promoter confers androgen-dependent transcriptional activation. (A) Schematic representation of human Cdc6 promoter-luciferase constructs. (B) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the pGL3-Cdc6-1.7 kb reporter construct and then treated with or without 10 nM R1881 for 24 h. (C) LNCaP cells cultured in 10% FBS were transfected with pGL3-Cdc6-1.7 kb and then treated with 30 microM Casodex for 10 h. (D) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the indicated reporter constructs and then treated with or without 10 nM R1881 for 24 h. (E-G) DU145 cells cultured in 10% FBS were cotransfected with pGL2-Cdc6-ARE and the indicated nuclear receptor expression constructs and then treated with or without 10 nM R1881 (panel E) 10 nM dexamethasone (panel F) or 100 nM T3 (panel G) for 24 h. Whole cell extract were prepared and assayed for luciferase activity. Luciferase values are presented as the mean +/- SE of triplicate transfections.
###end p 41
###begin p 42
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 81 82 81 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 156 157 156 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 333 334 333 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 458 459 454 455 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 629 630 625 626 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 631 632 627 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 112 117 <span type="species:ncbi:9606">human</span>
The ARE in Cdc6 promoter confers androgen-dependent transcriptional activation. (A) Schematic representation of human Cdc6 promoter-luciferase constructs. (B) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the pGL3-Cdc6-1.7 kb reporter construct and then treated with or without 10 nM R1881 for 24 h. (C) LNCaP cells cultured in 10% FBS were transfected with pGL3-Cdc6-1.7 kb and then treated with 30 microM Casodex for 10 h. (D) Seventy-two hours post-androgen starvation, LNCaP cells were transfected with the indicated reporter constructs and then treated with or without 10 nM R1881 for 24 h. (E-G) DU145 cells cultured in 10% FBS were cotransfected with pGL2-Cdc6-ARE and the indicated nuclear receptor expression constructs and then treated with or without 10 nM R1881 (panel E) 10 nM dexamethasone (panel F) or 100 nM T3 (panel G) for 24 h. Whole cell extract were prepared and assayed for luciferase activity. Luciferase values are presented as the mean +/- SE of triplicate transfections.
###end p 42
###begin p 43
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 345 353 345 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 520 524 520 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 681 684 679 682 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGC</bold>
###xml 815 819 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 877 885 875 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 986 988 982 984 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CT</bold>
###xml 1014 1017 1008 1011 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACC</bold>
###xml 1140 1148 1134 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1219 1223 1213 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1302 1306 1296 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Given that the Cdc6 ARE comprises a consensus class I steroid hormone response element, we next asked whether the element might confer other steroid hormone responses. Consistent with this notion, transient overexpression of the glucocorticoid receptor in DU145 cells activated transcription from the pGL2-Cdc6-ARE reporter greater than 2-fold (Figure 4F), yet overexpression of the class II thyroid hormone receptor elicited no response in the presence of its cognate ligand (Figure 4G). To further examine whether the Cdc6 ARE region is directly responsible for the observed androgen-induced transcription, we carried out site-directed mutagenesis of the putative ARE (AGAACA-->AAGCCA) within the context of the pGL2-Cdc6-ARE reporter construct (see 'Materials and Methods' section). As expected, mutation of the Cdc6 ARE significantly decreased R1881-induced transcription (Figure 4D). In contrast, two different site-directed mutations of the putative GATA site (mutant 1: AGATA-->ACTTA and mutant 2: AGATA-->AACCA) within the context of the pGL2-Cdc6-ARE reporter had only a modest inhibitory effect on R1881-stimulated transcription (Figure 4D). In summary, our data demonstrate that the novel ARE located within Cdc6 promoter (-734 bp to -720 bp) is functionally required for androgen-dependent Cdc6 gene expression, whereas a functional role for the downstream GATA site remains unclear (see 'Discussion' section).
###end p 43
###begin title 44
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Androgen- and antiandrogen-induced coregulator recruitment and covalent histone modifications at the Cdc6 gene promoter in prostate cancer cells
###end title 44
###begin p 45
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 508 512 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 706 710 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 721 729 721 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 814 818 814 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 864 872 864 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 948 952 948 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1230 1234 1230 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1245 1254 1245 1254 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 1367 1371 1367 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1381 1388 1381 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1391 1392 1391 1392 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1432 1436 1432 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1565 1566 1565 1566 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1571 1572 1571 1572 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1658 1659 1657 1658 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2123 2124 2106 2107 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2129 2130 2112 2113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1254 2304 1254 2285 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="46">Androgen- and antiandrogen-induced recruitment of coregulatory factors and covalent histone modifications at the <italic>Cdc6</italic> promoter <italic>in vivo</italic>. (<bold>A</bold>) Schematic representation of the human <italic>Cdc6</italic> promoter showing PCR primers used for ChIP. LNCaP cells were androgen-starved for 72 h and then treated with 10 nM DHT for 4 h (<bold>B</bold> and <bold>D</bold>), or cultured in normal serum for 72 h and then treated with 30 &#956;M Casodex for 2 h (<bold>C</bold>). ChIP was then performed using the specific antibodies indicated on the left-hand side of the panels followed by semi-quantitative PCR. Anti-acetylated-histone H3 is indicated by &#945;-H3-Ac; anti-dimethylated-histone H3-Arg17 is indicated by &#945;-H3R17-2me; anti-dimethylated-histone H3-Lys4 is indicated by &#945;-H3K4-2me; and anti-trimethylated-histone H3-Lys9 is indicated by &#945;-H3K9-3me. Quantitative image processing of the PCR data can be found in <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp510/DC1">Supplementary Figure S1</ext-link>. (<bold>E</bold> and <bold>F</bold>) ChIP was carried out as described in (B)&#8211;(D) followed by real-time PCR using the indicated PCR primer sets. Bar graph shows results as the mean &#177; SE of triplicate assays.</p>
###xml 1254 2304 1254 2285 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="46">Androgen- and antiandrogen-induced recruitment of coregulatory factors and covalent histone modifications at the <italic>Cdc6</italic> promoter <italic>in vivo</italic>. (<bold>A</bold>) Schematic representation of the human <italic>Cdc6</italic> promoter showing PCR primers used for ChIP. LNCaP cells were androgen-starved for 72 h and then treated with 10 nM DHT for 4 h (<bold>B</bold> and <bold>D</bold>), or cultured in normal serum for 72 h and then treated with 30 &#956;M Casodex for 2 h (<bold>C</bold>). ChIP was then performed using the specific antibodies indicated on the left-hand side of the panels followed by semi-quantitative PCR. Anti-acetylated-histone H3 is indicated by &#945;-H3-Ac; anti-dimethylated-histone H3-Arg17 is indicated by &#945;-H3R17-2me; anti-dimethylated-histone H3-Lys4 is indicated by &#945;-H3K4-2me; and anti-trimethylated-histone H3-Lys9 is indicated by &#945;-H3K9-3me. Quantitative image processing of the PCR data can be found in <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp510/DC1">Supplementary Figure S1</ext-link>. (<bold>E</bold> and <bold>F</bold>) ChIP was carried out as described in (B)&#8211;(D) followed by real-time PCR using the indicated PCR primer sets. Bar graph shows results as the mean &#177; SE of triplicate assays.</p></caption>
###xml 2304 2304 2285 2285 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f5"/>
###xml 1245 2304 1245 2285 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="46">Androgen- and antiandrogen-induced recruitment of coregulatory factors and covalent histone modifications at the <italic>Cdc6</italic> promoter <italic>in vivo</italic>. (<bold>A</bold>) Schematic representation of the human <italic>Cdc6</italic> promoter showing PCR primers used for ChIP. LNCaP cells were androgen-starved for 72 h and then treated with 10 nM DHT for 4 h (<bold>B</bold> and <bold>D</bold>), or cultured in normal serum for 72 h and then treated with 30 &#956;M Casodex for 2 h (<bold>C</bold>). ChIP was then performed using the specific antibodies indicated on the left-hand side of the panels followed by semi-quantitative PCR. Anti-acetylated-histone H3 is indicated by &#945;-H3-Ac; anti-dimethylated-histone H3-Arg17 is indicated by &#945;-H3R17-2me; anti-dimethylated-histone H3-Lys4 is indicated by &#945;-H3K4-2me; and anti-trimethylated-histone H3-Lys9 is indicated by &#945;-H3K9-3me. Quantitative image processing of the PCR data can be found in <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp510/DC1">Supplementary Figure S1</ext-link>. (<bold>E</bold> and <bold>F</bold>) ChIP was carried out as described in (B)&#8211;(D) followed by real-time PCR using the indicated PCR primer sets. Bar graph shows results as the mean &#177; SE of triplicate assays.</p></caption><graphic xlink:href="gkp510f5"/></fig>
###xml 1426 1431 <span type="species:ncbi:9606">human</span>
Our findings showing that androgens and antiandrogens modulate Cdc6 transcription, and that AR directly binds at a novel ARE in the Cdc6 gene promoter, strongly suggest that AR targets the Cdc6 gene for transcriptional regulation. Importantly, AR transcriptional activity in prostate cells is critically dependent on its interaction with accessory coregulatory factors and enzymes, and its subsequent recruitment of these cofactors to its respective target genes (6,7). To better understand how AR regulates Cdc6 gene expression, we performed ChIP assays with LNCaP cells treated with androgen (DHT) or antiandrogen (Casodex) using both semi-quantitative and real time PCR with primers spanning the ARE in Cdc6 promoter (Figure 5A). Of note, anti-AR antibodies revealed strong ligand-dependent AR occupancy at the Cdc6 ARE in the presence of both DHT and Casodex (Figure 5B, C and E). In order to identify specific cofactors recruited by AR to the Cdc6 promoter, antibodies against known NR transcriptional coactivators and corepressors were utilized. Furthermore, antibodies specific for acetylated or methylated histone H3 were employed to identify androgen- and antiandrogen-induced alterations in histone modifications at the Cdc6 promoter. Figure 5.Androgen- and antiandrogen-induced recruitment of coregulatory factors and covalent histone modifications at the Cdc6 promoter in vivo. (A) Schematic representation of the human Cdc6 promoter showing PCR primers used for ChIP. LNCaP cells were androgen-starved for 72 h and then treated with 10 nM DHT for 4 h (B and D), or cultured in normal serum for 72 h and then treated with 30 muM Casodex for 2 h (C). ChIP was then performed using the specific antibodies indicated on the left-hand side of the panels followed by semi-quantitative PCR. Anti-acetylated-histone H3 is indicated by alpha-H3-Ac; anti-dimethylated-histone H3-Arg17 is indicated by alpha-H3R17-2me; anti-dimethylated-histone H3-Lys4 is indicated by alpha-H3K4-2me; and anti-trimethylated-histone H3-Lys9 is indicated by alpha-H3K9-3me. Quantitative image processing of the PCR data can be found in . (E and F) ChIP was carried out as described in (B)-(D) followed by real-time PCR using the indicated PCR primer sets. Bar graph shows results as the mean +/- SE of triplicate assays.
###end p 45
###begin p 46
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 127 134 127 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 137 138 137 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 311 312 311 312 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 317 318 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 404 405 403 404 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 869 870 852 853 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 875 876 858 859 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 172 177 <span type="species:ncbi:9606">human</span>
Androgen- and antiandrogen-induced recruitment of coregulatory factors and covalent histone modifications at the Cdc6 promoter in vivo. (A) Schematic representation of the human Cdc6 promoter showing PCR primers used for ChIP. LNCaP cells were androgen-starved for 72 h and then treated with 10 nM DHT for 4 h (B and D), or cultured in normal serum for 72 h and then treated with 30 muM Casodex for 2 h (C). ChIP was then performed using the specific antibodies indicated on the left-hand side of the panels followed by semi-quantitative PCR. Anti-acetylated-histone H3 is indicated by alpha-H3-Ac; anti-dimethylated-histone H3-Arg17 is indicated by alpha-H3R17-2me; anti-dimethylated-histone H3-Lys4 is indicated by alpha-H3K4-2me; and anti-trimethylated-histone H3-Lys9 is indicated by alpha-H3K9-3me. Quantitative image processing of the PCR data can be found in . (E and F) ChIP was carried out as described in (B)-(D) followed by real-time PCR using the indicated PCR primer sets. Bar graph shows results as the mean +/- SE of triplicate assays.
###end p 46
###begin p 47
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 588 613 588 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">prostate specific antigen</italic>
###xml 615 618 615 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 748 751 748 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
Mediator is a conserved transcriptional coregulatory complex that plays a vital role in nuclear hormone receptor (NR)-regulated gene expression (8,9). The complex binds to DNA-bound NRs and promotes the assembly and activation of RNA pol II and its associated factors at core promoters and may also play a role in facilitating the recruitment of histone-modifying enzymes. A single subunit of the complex termed MED1 targets Mediator to AR and other NRs in the presence of their cognate ligand. A recent study found that MED1 was indispensable for androgen-dependent transcription of the prostate specific antigen (PSA) gene in LNCaP cells and that RNAi silencing of MED1 was accompanied by a significant reduction in RNA pol II recruitment at the PSA gene promoter (37). Consistent with these findings, our lab recently found that MED1 silencing in LNCaP cells markedly inhibited androgen-dependent cellular proliferation and progression into the G2/M phase of the cell cycle (38).
###end p 47
###begin p 48
###xml 269 272 269 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 376 384 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 752 760 752 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
Given the importance of MED1-Mediator in prostate cancer cell proliferation and cell-cycle progression, we first used anti-MED1 antibodies to precipitate formaldehyde cross-linked chromatin from DHT-stimulated LNCaP cells. Similar to previous LNCaP ChIP studies at the PSA gene promoter (28,37), we detected robust androgen-dependent recruitment of MED1 at the Cdc6 promoter (Figure 5B and E). Moreover, the androgen-dependent binding of other Mediator subunits (MED6, MED14 and MED17) support the notion that AR recruits the entire Mediator complex to the Cdc6 gene promoter. Significantly, and consistent with Mediator's role in facilitating the recruitment of RNA pol II (9), we also detected DHT-induced binding of RNA pol II at the Cdc6 promoter (Figure 5B and E).
###end p 48
###begin p 49
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 785 789 785 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 877 885 877 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1086 1094 1086 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1229 1230 1229 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1231 1232 1231 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1338 1342 1338 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1353 1361 1353 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1445 1446 1445 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1558 1561 1558 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 1568 1573 1568 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41 B42 B43">41&#8211;43</xref>
###xml 1627 1630 1627 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 1635 1639 1635 1639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Histone acetylation, a process dynamically controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs), has a profound impact on chromatin structure and consequently gene transcription (39). In general, acetylation of lysine residues on histones H3 and H4 facilitates transcriptional activation whereas deacetylation reverses this effect. The p160/SRC family of coactivators interact with NRs in a ligand-dependent manner and enhance their transcriptional transactivation (40). Two members of this family, p160/SRC-1 and p160/SRC-3, possess intrinsic HAT activity and bind and work together with other more potent HATs (CBP, p300 and PCAF) to acetylate histones. Interestingly, we detected strong DHT-dependent recruitment of both p160/SRC-1 and p160/SRC-3 at the Cdc6 promoter that was concomitantly associated with an increase in histone H3 acetylation (Figure 5B, D and E). By contrast, treatment of LNCaP cells with the antiandrogen Casodex triggered a pronounced decrease in histone H3 acetylation and was accompanied by the recruitment of HDACs-1, -2 and -3 (Figure 5C). The NR corepressors NCoR and SMRT, which directly bind to AR in the presence of antiandrogens, are thought to recruit HDACs to AR (6,7). Notably in this regard, we observed strong Casodex-dependent recruitment of SMRT, but not NCoR, to the Cdc6 promoter (Figure 5C). Although the recruitment of SMRT is consistent with transcriptional repression (6), the data contrasts earlier studies showing strong Casodex-dependent recruitment of both NCoR and SMRT at the PSA gene (41-43) and suggest that structural differences between the PSA and Cdc6 promoter/enhancer regions differentially influence AR-corepressor complex recruitment and binding.
###end p 49
###begin p 50
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 610 614 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 678 686 678 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1065 1069 1065 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1203 1207 1203 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Histone methylation has emerged as an equally important modification linked to both transcriptional activation and repression (39). In particular, methylation of histone H3-lysine 4 (H3K4) is associated with active transcription, while methylation of histone H3-lysine 9 (H3K9) is associated with gene silencing and heterochromatin formation (44). Furthermore, methylation of histone H3 arginine residues (R2, R17 and R26) are covalent modifications associated with ligand-dependent transcriptional activation by NRs (45). Strikingly, we observed a marked DHT-dependent decrease in H3K9 tri-methylation at the Cdc6 promoter as well as a modest increase in H3R17 di-methylation (Figure 5D and E), both marks consistent with Cdc6 transcriptional activation. By contrast, we failed to observe any significant increase in H3K4 methylation following addition of DHT. Collectively, these findings suggest that in addition to Mediator and HAT-containing coactivators, androgen-bound AR may also recruit H3K9-demethylase and H3-arginine-methyltransferase activities to the Cdc6 promoter (see 'Discussion' section). Conversely, antiandrogen-bound AR recruits SMRT-HDAC complexes that deacetylate histones at the Cdc6 promoter and facilitate gene silencing.
###end p 50
###begin title 51
AR promotes cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells
###end title 51
###begin p 52
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 235 240 235 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20 B21 B22">20&#8211;22</xref>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 817 825 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 829 838 829 838 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 1293 1294 1293 1294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1453 1454 1453 1454 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1597 1598 1593 1594 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1660 1664 1656 1660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1669 1673 1665 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 1674 1679 1667 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">actin</italic>
###xml 1682 1683 1675 1676 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1812 1813 1803 1804 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 838 1945 838 1936 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="53">AR promotes cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells. LNCaP cells cultured in normal serum were first transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then synchronized in the G1/S phase via thymidine block or in the G2/M phase via nocodazole treatment. Untreated (unsynchronized) cells were used as controls. Cell-cycle distribution of the synchronized LNCaP cells was determined by flow cytometry. (<bold>A</bold>) The mean average of the percentage of cells in the sub-G0, G1/S and G2/M phases of the cell cycle from three separate synchronization experiments is shown. (<bold>B</bold>) Whole-cell extract was prepared and equivalent amounts of protein were probed by immunoblot using anti-AR or anti-&#945;-tubulin antibodies. (<bold>C</bold>) Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;</italic>-<italic>actin</italic>. (<bold>D</bold>) RNA samples from (C) were analyzed using real-time PCR. Bar graph represents results as the mean &#177; SE of triplicate assays. (<bold>E</bold>) ChIP was were carried out as described in Figure 6 using PCR primer set A. Non-specific rabbit IgG was used as a negative control.</p>
###xml 838 1945 838 1936 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="53">AR promotes cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells. LNCaP cells cultured in normal serum were first transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then synchronized in the G1/S phase via thymidine block or in the G2/M phase via nocodazole treatment. Untreated (unsynchronized) cells were used as controls. Cell-cycle distribution of the synchronized LNCaP cells was determined by flow cytometry. (<bold>A</bold>) The mean average of the percentage of cells in the sub-G0, G1/S and G2/M phases of the cell cycle from three separate synchronization experiments is shown. (<bold>B</bold>) Whole-cell extract was prepared and equivalent amounts of protein were probed by immunoblot using anti-AR or anti-&#945;-tubulin antibodies. (<bold>C</bold>) Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;</italic>-<italic>actin</italic>. (<bold>D</bold>) RNA samples from (C) were analyzed using real-time PCR. Bar graph represents results as the mean &#177; SE of triplicate assays. (<bold>E</bold>) ChIP was were carried out as described in Figure 6 using PCR primer set A. Non-specific rabbit IgG was used as a negative control.</p></caption>
###xml 1945 1945 1936 1936 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f6"/>
###xml 829 1945 829 1936 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="53">AR promotes cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells. LNCaP cells cultured in normal serum were first transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then synchronized in the G1/S phase via thymidine block or in the G2/M phase via nocodazole treatment. Untreated (unsynchronized) cells were used as controls. Cell-cycle distribution of the synchronized LNCaP cells was determined by flow cytometry. (<bold>A</bold>) The mean average of the percentage of cells in the sub-G0, G1/S and G2/M phases of the cell cycle from three separate synchronization experiments is shown. (<bold>B</bold>) Whole-cell extract was prepared and equivalent amounts of protein were probed by immunoblot using anti-AR or anti-&#945;-tubulin antibodies. (<bold>C</bold>) Total RNA was analyzed by RT&#8211;PCR using primers specific for <italic>Cdc6</italic> and <italic>&#946;</italic>-<italic>actin</italic>. (<bold>D</bold>) RNA samples from (C) were analyzed using real-time PCR. Bar graph represents results as the mean &#177; SE of triplicate assays. (<bold>E</bold>) ChIP was were carried out as described in Figure 6 using PCR primer set A. Non-specific rabbit IgG was used as a negative control.</p></caption><graphic xlink:href="gkp510f6"/></fig>
###xml 1903 1909 <span type="species:ncbi:9986">rabbit</span>
AR is thought to act as a master regulator of G1-S phase progression in androgen-dependent prostate cancer cells (12). In most of the immortalized mammalian cell lines tested thus far, Cdc6 mRNA expression peaks during the G1/S phase (20-22). In view of our data showing that AR binds at Cdc6 promoter and regulates transcription in a ligand-dependent manner, we investigated whether AR is involved in regulating cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells. LNCaP cells grown in normal serum were first transfected with AR siRNA or a non-specific control siRNA and then synchronized in G1/S via thymidine block or in G2/M via nocodazole treatment (see 'Materials and Methods' section). Synchronization was confirmed by flow cytometry and untreated (unsynchronized) cells were used as controls (Figure 6A). Figure 6.AR promotes cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells. LNCaP cells cultured in normal serum were first transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then synchronized in the G1/S phase via thymidine block or in the G2/M phase via nocodazole treatment. Untreated (unsynchronized) cells were used as controls. Cell-cycle distribution of the synchronized LNCaP cells was determined by flow cytometry. (A) The mean average of the percentage of cells in the sub-G0, G1/S and G2/M phases of the cell cycle from three separate synchronization experiments is shown. (B) Whole-cell extract was prepared and equivalent amounts of protein were probed by immunoblot using anti-AR or anti-alpha-tubulin antibodies. (C) Total RNA was analyzed by RT-PCR using primers specific for Cdc6 and beta-actin. (D) RNA samples from (C) were analyzed using real-time PCR. Bar graph represents results as the mean +/- SE of triplicate assays. (E) ChIP was were carried out as described in Figure 6 using PCR primer set A. Non-specific rabbit IgG was used as a negative control.
###end p 52
###begin p 53
###xml 455 456 455 456 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 615 616 615 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 759 760 755 756 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 822 826 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 831 835 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 836 841 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">actin</italic>
###xml 844 845 837 838 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 974 975 965 966 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1065 1071 <span type="species:ncbi:9986">rabbit</span>
AR promotes cell-cycle-dependent Cdc6 mRNA expression in prostate cancer cells. LNCaP cells cultured in normal serum were first transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then synchronized in the G1/S phase via thymidine block or in the G2/M phase via nocodazole treatment. Untreated (unsynchronized) cells were used as controls. Cell-cycle distribution of the synchronized LNCaP cells was determined by flow cytometry. (A) The mean average of the percentage of cells in the sub-G0, G1/S and G2/M phases of the cell cycle from three separate synchronization experiments is shown. (B) Whole-cell extract was prepared and equivalent amounts of protein were probed by immunoblot using anti-AR or anti-alpha-tubulin antibodies. (C) Total RNA was analyzed by RT-PCR using primers specific for Cdc6 and beta-actin. (D) RNA samples from (C) were analyzed using real-time PCR. Bar graph represents results as the mean +/- SE of triplicate assays. (E) ChIP was were carried out as described in Figure 6 using PCR primer set A. Non-specific rabbit IgG was used as a negative control.
###end p 53
###begin p 54
###xml 112 120 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 197 205 197 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 387 395 387 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 534 542 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 625 629 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 662 670 662 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 765 769 765 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
Similar to previous findings, we observed that Cdc6 mRNA levels in LNCaP cells are higher at G1/S than at G2/M (Figure 6C and D, left panels). AR protein levels also peak at G1/S relative to G2/M (Figure 6B, left panels) and when ChIP assays were performed using synchronized LNCaP cells, we detected a markedly higher occupancy of AR at the Cdc6 gene promoter at G1/S relative to G2/M (Figure 6E, left panels). Interestingly, when LNCaP cells were transfected with AR siRNA, there was a notable decrease in Cdc6 mRNA levels at G1/S (Figure 6C and D, right panels) that was accompanied by a sharp loss of AR occupancy at the Cdc6 promoter as determined by ChIP (Figure 6E, right panels). These findings correlate elevated AR protein expression and occupancy at the Cdc6 gene at G1/S phase with elevated levels of Cdc6 mRNA at G1/S, and consistent with its presumptive role as a licensing factor for the onset of S phase, suggest that AR promotes cell-cycle-dependent expression of Cdc6 mRNA.
###end p 54
###begin title 55
AR silencing inhibits Cdc6 expression and cell-cycle progression
###end title 55
###begin p 56
###xml 455 463 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 545 553 545 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 776 784 776 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 871 875 871 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 1235 1244 1235 1244 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7.</label>
###xml 1311 1312 1311 1312 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1690 1691 1686 1687 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1742 1743 1734 1735 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1865 1866 1855 1856 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1244 2070 1244 2060 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="57">AR silencing inhibits Cdc6 expression and cell-cycle progression. (<bold>A</bold>) Whole cell extract prepared from LNCaP cells transfected with AR siRNA or a non-specific control siRNA (200 nM final) was probed by immunoblot with antibodies against AR, Cdc6 or &#945;-tubulin. Equal numbers of androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured with or without DHT (10 nM) for 2 days (<bold>B</bold>), with or without Casodex (30 &#181;M) for 2 days (<bold>C</bold>), after which time cell number was determined. Bar graph represents results as the mean &#177; SE of quadruplicate assays. (<bold>D</bold>) Androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured in DHT (10 nM) for 2 days after which time cell flow cytometry was performed.</p>
###xml 1244 2070 1244 2060 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="57">AR silencing inhibits Cdc6 expression and cell-cycle progression. (<bold>A</bold>) Whole cell extract prepared from LNCaP cells transfected with AR siRNA or a non-specific control siRNA (200 nM final) was probed by immunoblot with antibodies against AR, Cdc6 or &#945;-tubulin. Equal numbers of androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured with or without DHT (10 nM) for 2 days (<bold>B</bold>), with or without Casodex (30 &#181;M) for 2 days (<bold>C</bold>), after which time cell number was determined. Bar graph represents results as the mean &#177; SE of quadruplicate assays. (<bold>D</bold>) Androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured in DHT (10 nM) for 2 days after which time cell flow cytometry was performed.</p></caption>
###xml 2070 2070 2060 2060 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkp510f7"/>
###xml 1235 2070 1235 2060 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7.</label><caption><p textid="57">AR silencing inhibits Cdc6 expression and cell-cycle progression. (<bold>A</bold>) Whole cell extract prepared from LNCaP cells transfected with AR siRNA or a non-specific control siRNA (200 nM final) was probed by immunoblot with antibodies against AR, Cdc6 or &#945;-tubulin. Equal numbers of androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured with or without DHT (10 nM) for 2 days (<bold>B</bold>), with or without Casodex (30 &#181;M) for 2 days (<bold>C</bold>), after which time cell number was determined. Bar graph represents results as the mean &#177; SE of quadruplicate assays. (<bold>D</bold>) Androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured in DHT (10 nM) for 2 days after which time cell flow cytometry was performed.</p></caption><graphic xlink:href="gkp510f7"/></fig>
Given the importance of Cdc6 in regulating DNA replication, we asked whether loss of AR-mediated Cdc6 expression negatively effects androgen-dependent prostate cancer cell proliferation. Toward that end, equal numbers of androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA and then cultured with or without DHT for 2 days. In agreement with our earlier results, AR silencing concomitantly inhibits Cdc6 expression (Figure 7A) and in turn, dramatically decreases androgen-dependent cellular proliferation (Figure 7B). Indeed, loss of AR decreased the average DHT-induced LNCaP cell number by 61%, and consistent with a critical requirement for Cdc6 at the onset of S phase, loss of AR triggers cell-cycle arrest in the G0 and G1 phases (Figure 7D). Interestingly, we have also found that silencing of MED1, a key AR coactivator for Cdc6 transcription, likewise inhibited Cdc6 expression, decreased androgen-dependent proliferation, and triggered cell-cycle arrest in G1 phase (38). These results support the notion that AR and its associated coregulatory factors play an important role in licensing DNA replication by regulating the expression of Cdc6 and possibly other key replication factors. Figure 7.AR silencing inhibits Cdc6 expression and cell-cycle progression. (A) Whole cell extract prepared from LNCaP cells transfected with AR siRNA or a non-specific control siRNA (200 nM final) was probed by immunoblot with antibodies against AR, Cdc6 or alpha-tubulin. Equal numbers of androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured with or without DHT (10 nM) for 2 days (B), with or without Casodex (30 microM) for 2 days (C), after which time cell number was determined. Bar graph represents results as the mean +/- SE of quadruplicate assays. (D) Androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured in DHT (10 nM) for 2 days after which time cell flow cytometry was performed.
###end p 56
###begin p 57
###xml 67 68 67 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 446 447 442 443 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 498 499 490 491 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 621 622 611 612 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
AR silencing inhibits Cdc6 expression and cell-cycle progression. (A) Whole cell extract prepared from LNCaP cells transfected with AR siRNA or a non-specific control siRNA (200 nM final) was probed by immunoblot with antibodies against AR, Cdc6 or alpha-tubulin. Equal numbers of androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured with or without DHT (10 nM) for 2 days (B), with or without Casodex (30 microM) for 2 days (C), after which time cell number was determined. Bar graph represents results as the mean +/- SE of quadruplicate assays. (D) Androgen-starved LNCaP cells were transfected with AR siRNA or a non-specific control siRNA (200 nM final) and then cultured in DHT (10 nM) for 2 days after which time cell flow cytometry was performed.
###end p 57
###begin title 58
DISCUSSION
###end title 58
###begin p 59
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 580 584 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
In eukaryotic cells, Cdc6 plays a crucial functional role late in G1 phase by regulating the formation of pre-replication complexes that allow for the initiation of DNA synthesis at S phase. Indeed, whether or not Cdc6 is loaded on chromatin at the origins of DNA replication is believed to distinguish between cells that will continue through G1 to S phase versus those that will enter quiescence (17). Given its functional importance, Cdc6 expression is tightly regulated at the level of transcription, protein phosphorylation, and protein turnover (18,19). In mammalian cells, Cdc6 gene expression peaks at G1/S and is dependent on the presence of two E2F-binding sites in the proximal promoter which have been shown to confer both positive and negative transcriptional responses (20,21). G1 cyclins and cyclin dependent kinases have been proposed to activate promoter-bound E2F in mid to late G1 via the phosphorylation and displacement of inhibitory retinoblastoma (Rb) proteins (22).
###end p 59
###begin p 60
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 777 781 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 956 960 956 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1124 1127 1124 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc</italic>
Mallik et al. (25) first demonstrated the importance of an ARE in the Cdc6 promoter using luciferase assays, mutagenesis and ChIP in prostate cancer xenografts and cell lines. The study presented here extends this previous work with two important findings. First, we show for the first time that Cdc6 expression is under the regulatory control of AR in a cell-cycle dependent manner. Given the functional importance of Cdc6 in DNA replication, our results implicate the Cdc6 gene as a key regulatory target in AR-signaling pathways and provide new insights into AR's presumptive role as a master regulator of G1-S phase progression. Indeed, given that AR-signaling pathways become aberrantly hyperactivated in neoplastic prostate cells (10), it is conceivable that deregulated Cdc6 gene expression may promote prostate cancer cell growth and progression. Secondly, we have identified several specific coactivators and corepressors involved in AR-dependent Cdc6 transcriptional regulation and have further characterized androgen- and antiandrogen-induced alterations in histone H3 acetylation and methylation patterns at the Cdc6 promoter. Thus, the findings here have important implications for the fundamental molecular mechanisms used by AR to regulate transcription.
###end p 60
###begin p 61
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 418 422 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 555 559 555 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 611 619 611 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 831 832 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 903 907 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 950 958 950 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1146 1150 1146 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1169 1176 1169 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Considering the fact that other steroid NRs (e.g. the progesterone and glucocorticoid receptors) are potent regulators of cellular proliferation and G1-S phase progression (46), it is interesting to note that the ARE found in the Cdc6 promoter (AGAACAnnnTATTCT) constitutes a near perfect class I steroid hormone response element (34). Thus, other NRs in unrelated steroid hormone-responsive tissues might also target Cdc6 for transcriptional regulation. Consistent with this notion, we observed a modest yet reproducible ligand-dependent activation of a Cdc6-ARE reporter gene via the glucocorticoid receptor (Figure 4F). Binding sites for the GATA and ETS families of transcription factors have been identified proximal to AREs in the genome (35) and both types of factors have been proposed to facilitate AR binding to the ARE (3). Interestingly, both GATA and ETS-binding sites were detected in the Cdc6 gene promoter just downstream of the ARE (Figure 2A). Although we were unable to discern a functional requirement for either factor in the studies here, it remains plausible that GATA and/or ETS factors cooperate with AR in mediating the Cdc6 androgen response in vivo.
###end p 61
###begin p 62
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 404 408 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 607 611 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 1186 1188 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 1314 1316 1314 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 1317 1319 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 1320 1322 1320 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
Significantly, we identified several of the transcriptional coregulatory factors involved in AR-dependent transcriptional regulation of the Cdc6 gene and further characterized androgen- and antiandrogen-induced alterations in histone H3 acetylation and methylation patterns at the Cdc6 promoter. Our findings show that in the presence of androgens, AR recruits Mediator and p160/SRC-HAT complexes to the Cdc6 promoter, which in turn facilitate histone acetylation at the promoter region and the recruitment of RNA pol II. Contrarily, in the presence of antiandrogens, AR recruits SMRT-HDAC complexes to the Cdc6 promoter that in turn facilitate histone deacetylation. We also observed a pronounced androgen-dependent decrease in H3K9 tri-methylation at the Cdc6 promoter as well as a modest increase in H3R17 di-methylation, both marks consistent with transcriptional activation (39). These findings suggest that in addition to the aforementioned coactivators, androgen-bound AR also recruits the histone H3-arginine methyltransferase CARM1 (which specifically facilitates H3R17 methylation) (47) and the histone H3-lysine demethylase JMJD2C (which specifically demethylates H3K9-3me) (48). Importantly, both CARM1 and JMJD2C have been previously shown to associate with AR and enhance AR-dependent transcription (41,47,49).
###end p 62
###begin p 63
###xml 179 187 179 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 527 531 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 601 604 601 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 720 723 720 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1012 1016 1012 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
In agreement with our findings showing that AR silencing in LNCaP cells decreases Cdc6 expression, inhibits androgen-induced cell growth and triggers G0 and G1 cell-cycle arrest (Figure 7), we have likewise found that MED1 silencing in LNCaP cells also inhibits Cdc6 expression and decreases androgen-dependent progression into G2/M phase (38). These data, together with the ChIP findings discussed above, suggest that MED1-Mediator plays a particularly important coactivator role in AR-dependent transcriptional activation of Cdc6. Indeed, MED1 is indispensable for AR-dependent transcription of the PSA gene in LNCaP cells and MED1 silencing was accompanied by a significant reduction in RNA pol II recruitment at the PSA gene promoter (37). Thus in addition to the covalent histone modifications and chromatin remodeling events fulfilled by other types of AR coactivators, MED1-Mediator likely plays a rate-limiting role in facilitating the assembly and activation of RNA pol II and its associated factors at Cdc6 and other AR target genes.
###end p 63
###begin p 64
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 424 432 424 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 490 494 490 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 788 792 788 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 1014 1018 1014 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1135 1139 1135 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdc6</italic>
A flow cytometry approach was recently utilized to show that AR is degraded at the M phase of each cell cycle in different prostate cancer cell lines thus suggesting that mitotic AR degradation may be a requirement to license a new round of DNA replication (13). Consistent with a presumptive role as a DNA replication-licensing factor, we found that AR levels in LNCaP cells were significantly higher at G1/S than at G2/M (Figure 6). Furthermore, we found that peak occupancy of AR at the Cdc6 promoter occurs during the G1/S phase of the cell cycle, concomitant with peak Cdc6 mRNA expression, and when LNCaP cells were transfected with AR siRNA, there was notable decrease in Cdc6 mRNA levels at G1/S. These findings suggest that AR cooperates with E2F to promote cell-cycle-dependent Cdc6 gene expression. Interestingly, it has been reported that AR can directly interact with Rb proteins (50,51). Thus, in addition to the transactivation mechanisms outlined above, AR might also form complexes with Rb at the Cdc6 promoter that alleviate inhibitory constraints on promoter-bound E2F factors (25). In sum, our results suggest that Cdc6 is a key-regulatory target gene in androgen-sensitive prostate cells and help clarify the molecular role of AR during G1-S phase progression of the mammalian cell cycle.
###end p 64
###begin title 65
SUPPLEMENTARY DATA
###end title 65
###begin p 66
 are available at NAR Online.
###end p 66
###begin title 67
[Supplementary Data]
###end title 67
###begin title 68
FUNDING
###end title 68
###begin p 69
###xml 0 29 0 29 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health</funding-source>
###xml 37 45 37 45 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DK054030</award-id>
###xml 90 119 90 119 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health</funding-source>
National Institutes of Health grant (DK054030 to J.D.F.). Funding for open access charge: National Institutes of Health.
###end p 69
###begin p 70
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 70
###begin title 71
ACKNOWLEDGEMENTS
###end title 71
###begin p 72
The authors wish to thank Drs Joseph Nevins, Frank Claessens, Herb Samuels and Michael Garabedian for plasmids; Theresa Hyejeong Choi for assistance with the flow cytometry analyses; Drs Paul Yen, Madesh Belakavadi and Ravi Vijavargia for critically reading the manuscript; and AstraZeneca for kindly providing the Casodex used in this work.
###end p 72
###begin title 73
REFERENCES
###end title 73
###begin article-title 74
Androgen receptor structural and functional elements: role and regulation in prostate cancer
###end article-title 74
###begin article-title 75
Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation
###end article-title 75
###begin article-title 76
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
###end article-title 76
###begin article-title 77
Cell- and gene-specific regulation of primary target genes by the androgen receptor
###end article-title 77
###begin article-title 78
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
###end article-title 78
###begin article-title 79
Androgen receptor (AR) coregulators: an overview
###end article-title 79
###begin article-title 80
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer
###end article-title 80
###begin article-title 81
Dynamic regulation of pol II transcription by the mammalian Mediator complex
###end article-title 81
###begin article-title 82
Role of the mediator complex in nuclear hormone receptor signaling
###end article-title 82
###begin article-title 83
The development of androgen-independent prostate cancer
###end article-title 83
###begin article-title 84
Molecular genetics of prostate cancer
###end article-title 84
###begin article-title 85
AR, the cell cycle, and prostate cancer
###end article-title 85
###begin article-title 86
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
###end article-title 86
###begin article-title 87
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
###end article-title 87
###begin article-title 88
###xml 43 46 <span type="species:ncbi:10116">rat</span>
Activation of programmed cell death in the rat ventral prostate after castration
###end article-title 88
###begin article-title 89
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells
###end article-title 89
###begin article-title 90
What's taking so long? S-phase entry from quiescence versus proliferation
###end article-title 90
###begin article-title 91
Replication licensing and cancer - a fatal entanglement?
###end article-title 91
###begin article-title 92
CDKs give cdc6 a license to drive into S phase
###end article-title 92
###begin article-title 93
Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells
###end article-title 93
###begin article-title 94
Cell cycle-regulated expression of mammalian CDC6 Is dependent on E2F
###end article-title 94
###begin article-title 95
Regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F
###end article-title 95
###begin article-title 96
Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase
###end article-title 96
###begin article-title 97
Down-regulation of Cdc6, a cell cycle regulatory gene, in prostate cancer
###end article-title 97
###begin article-title 98
Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells
###end article-title 98
###begin article-title 99
Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells
###end article-title 99
###begin article-title 100
Activation of TRAP/Mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation
###end article-title 100
###begin article-title 101
A coregulatory role for the TRAP-Mediator complex in androgen receptor-mediated gene expression
###end article-title 101
###begin article-title 102
Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo
###end article-title 102
###begin article-title 103
Molecular mechanisms underlying KVS-1-MPS-1 complex assembly
###end article-title 103
###begin article-title 104
Role of SRC-1 in the promotion of prostate pancer cell growth and tumor progression
###end article-title 104
###begin article-title 105
###xml 54 59 <span type="species:ncbi:9606">human</span>
Identification of genes periodically expressed in the human cell cycle and their expression in tumors
###end article-title 105
###begin article-title 106
###xml 74 79 <span type="species:ncbi:9606">human</span>
Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells
###end article-title 106
###begin article-title 107
Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression
###end article-title 107
###begin article-title 108
Androgen receptor binding sites identified by a GREF_GATA Model
###end article-title 108
###begin article-title 109
Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation
###end article-title 109
###begin article-title 110
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking
###end article-title 110
###begin article-title 111
A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression
###end article-title 111
###begin article-title 112
The complex language of chromatin regulation during transcription
###end article-title 112
###begin article-title 113
Nuclear receptor coregulators: cellular and molecular biology
###end article-title 113
###begin article-title 114
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor
###end article-title 114
###begin article-title 115
The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor
###end article-title 115
###begin article-title 116
Formation of the androgen receptor transcription complex
###end article-title 116
###begin article-title 117
Regulation of histone methylation by demethylimination and demethylation
###end article-title 117
###begin article-title 118
Role of protein methylation in chromatin remodeling and transcriptional regulation
###end article-title 118
###begin article-title 119
The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression
###end article-title 119
###begin article-title 120
Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-Catenin with two different classes of DNA-binding transcriptional activators
###end article-title 120
###begin article-title 121
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression
###end article-title 121
###begin article-title 122
Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability
###end article-title 122
###begin article-title 123
The retinoblastoma protein-associated transcription repressor RBaK interacts with the androgen receptor and enhances its transcriptional activity
###end article-title 123
###begin article-title 124
Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein
###end article-title 124

